Journal
BRAIN PATHOLOGY
Volume 25, Issue 6, Pages 755-759Publisher
WILEY
DOI: 10.1111/bpa.12307
Keywords
drug resistance; glioblastoma; metabolic reprogramming; mTORC2; nutrient
Categories
Funding
- National Institute for Neurological Diseases and Stroke [NS73831]
- Defeat GBM Research Collaborative, a subsidiary of National Brain Tumor Society
- National Cancer Institute Grant [CA119347]
- Ben and Catherine Ivy Foundation
- Ichiro Kanehara Foundation
- Uehara Memorial Foundation
- Novartis Foundation (Japan) for Promotion of Science
- JSPS KAKENHI [15K19067]
- Grants-in-Aid for Scientific Research [15K19067] Funding Source: KAKEN
Ask authors/readers for more resources
Metabolic reprogramming is a central hallmark of cancer, enabling tumor cells to obtain the macromolecular precursors and energy needed for rapid tumor growth. Understanding how oncogenes coordinate altered signaling with metabolic reprogramming and how cancer cells harness cellular metabolism and its metabolites for their survival may yield new insights into tumor pathogenesis. Here, we review the recently identified central regulatory role for mTORC2, a downstream effector of many cancer-causing mutations, in metabolic reprogramming and cancer drug resistance in glioblastoma. We further consider the emerging concept that mTORC2 may connect genetics with environmental alterations in brain cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available